- Clearmind Medicine (CSE:CMND) has agreed to collaborate on product development with pharmaceutical and consumer products company CTS Ltd.
- The biotech company will have access to CTS’s state-of-the-art facilities under the collaboration, allowing it to expand its research and development capabilities
- CTS imports, registers, markets and distributes healthcare products of leading global pharmaceutical companies across Israel
- Clearmind Medicine Inc. opened trading at $0.53 per share
Clearmind Medicine (CSE:CMND) has agreed to collaborate on product development with pharmaceutical and consumer products company CTS Ltd.
The biotech company will have access to CTS’s state-of-the-art facilities under the collaboration, allowing it to expand its research and development capabilities. It will also have access to CTS’s global networks and industry connections, as well as the ability to leverage CTS’s expertise in manufacturing and marketing, and could benefit from CTS’s vast industry experience and guidance.
CTS imports, registers, markets, and distributes healthcare products of leading global pharmaceutical companies across Israel.
Clearmind Chief Executive Officer Dr. Adi Zuloff-Shani said CTS’s support and expertise will be invaluable as her team advances its research and development efforts in psychedelic-based therapeutics.
“This significant milestone recognizes Clearmind Medicine’s innovative approach as well as highlights the growing interest in the field of psychedelic-based therapies within the pharmaceutical industry. Together, we have the opportunity to revolutionize mental health treatments and provide much-needed relief to individuals suffering from a range of mental health conditions,” Zuloff-Shani said in a statement.
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. Its objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company’s intellectual portfolio consists of 14 patent families.
Clearmind Medicine Inc. opened trading at $0.53 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Clearmind Medicine Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.